Trial Profile
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Patiromer (Primary) ; Spironolactone (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Hyperkalaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms MAGMAAddOn
- 19 Oct 2021 Status changed from recruiting to discontinued.
- 30 Jul 2018 New trial record